Detalles de la búsqueda
1.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37311468
2.
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Leukemia
; 37(11): 2314-2318, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37752285
Resultados
1 -
2
de 2
1
Próxima >
>>